Q1 EPS Forecast for Axsome Therapeutics Raised by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at Zacks Research lifted their Q1 2025 EPS estimates for shares of Axsome Therapeutics in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the company will post earnings per share of ($1.33) for the quarter, up from their prior forecast of ($1.77). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.27) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.40) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at $0.29 EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.24) EPS.

AXSM has been the subject of a number of other reports. Morgan Stanley raised their price objective on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Mizuho lifted their target price on shares of Axsome Therapeutics from $195.00 to $212.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 26th. Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a “buy” rating and a $176.00 target price for the company. Royal Bank of Canada lifted their target price on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 19th. Finally, Wells Fargo & Company lifted their target price on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $167.36.

Axsome Therapeutics Trading Up 1.8 %

Shares of AXSM opened at $121.65 on Friday. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The firm has a 50 day simple moving average of $111.54 and a 200-day simple moving average of $98.58. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $139.13. The stock has a market cap of $5.93 billion, a price-to-earnings ratio of -20.31 and a beta of 1.00.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The business had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. BVF Inc. IL lifted its holdings in Axsome Therapeutics by 32.7% in the 4th quarter. BVF Inc. IL now owns 1,388,064 shares of the company’s stock worth $117,444,000 after buying an additional 342,064 shares in the last quarter. FMR LLC lifted its holdings in Axsome Therapeutics by 20.6% in the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after buying an additional 185,951 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Axsome Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 912,538 shares of the company’s stock worth $77,228,000 after buying an additional 4,079 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Axsome Therapeutics by 1.1% in the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock worth $66,750,000 after buying an additional 8,125 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Axsome Therapeutics by 10.8% in the 4th quarter. Invesco Ltd. now owns 692,464 shares of the company’s stock worth $58,589,000 after buying an additional 67,285 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Activity at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 22.40% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.